Skip to main content

Table 3 Comparison of clinical features based on histological subtype

From: Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)

Characteristics

DLBCL

No. (%)

MALT

No. (%)

BL

No. (%)

MCL

No. (%)

FL

No. (%)

PTCL-U

No. (%)

EATL

No. (%)

ENKTL

No. (%)

P value

Number of cases

386

61

31

19

7

34

25

18

 

Median age (range)

56 (15-92)

55 (15-80)

47 (15-78)

60 (42-78)

52 (39-81)

49 (15-78)

51 (23-75)

47 (32-72)

0.002

Age > 60, %

160 (41.5)

22 (36.1)

7 (22.6)

10 (52.6)

3 (42.9)

11 (32.4)

7 (28.0)

5 (27.8)

0.246

Male, %

240 (62.2)

32 (52.5)

25 (80.6)

13 (68.4)

4 (57.1)

24 (70.6)

17 (68.0)

12 (66.7)

0.273

Performance status ≥ 2, %

60 (15.6)

6 (9.8)

5 (16.1)

0 (0.0)

1 (14.3)

9 (26.5)

6 (24.0)

3 (16.7)

0.218

Lugano stage IV, %

94 (24.4)

7 (11.5)

17 (54.8)

15 (78.9)

3 (42.9)

15 (44.1)

8 (32.0)

9 (50.0)

< 0.001

Increased serum LDH, %

150 (39.9)

5 (8.5)

23 (76.7)

4 (21.1)

1 (14.3)

12 (36.4)

8 (34.8)

7 (38.9)

< 0.001

Presence of B symptoms, %

75 (19.5)

7 (11.5)

7 (22.6)

3 (15.8)

1 (14.3)

12 (35.3)

9 (36.0)

6 (35.3)

0.048

Extranodal involvement ≥ 2, %

93 (24.3)

3 (5.4)

18 (58.1)

9 (47.4)

2 (28.6)

10 (29.4)

10 (41.7)

10 (55.6)

< 0.001

IPI HI/H, %

93 (24.5)

5 (8.9)

15 (48.4)

7 (36.8)

1 (14.3)

9 (26.5)

6 (26.1)

4 (22.2)

0.008

Bone marrow invasion, %

20 (5.2)

4 (6.6)

7 (22.6)

5 (26.3)

0 (0.0)

3 (8.8)

3 (12.0)

1 (5.6)

< 0.001

Intestinal obstruction, %

69 (17.8)

7 (11.5)

6 (19.4)

0 (0.0)

2 (28.5)

4 (11.8)

4 (16.0)

4 (22.2)

0.398

Bleeding, %

8 (2.0)

2 (3.3)

1 (3.2)

0 (0.0)

0 (0.0)

1 (2.9)

1 (4.0)

0 (0.0)

0.964

Perforation, %

19 (4.9)

1 (1.6)

0 (0.0)

0 (0.0)

0 (0.0)

2 (5.9)

3 (12.0)

0 (0.0)

0.194

Small intestine, %

104 (26.9)

14 (23.0)

11 (35.5)

0 (0.0)

2 (28.6)

13 (38.2)

10 (40.0)

8 (44.4)

< 0.001

Ileocecal region, %

187 (48.4)

19 (31.1)

9 (29.0)

3 (15.8)

3 (42.9)

7 (20.6)

2 (8.0)

1 (5.6)

< 0.001

Large intestine, %

73 (18.9)

21 (34.4)

5 (16.1)

5 (26.3)

2 (28.6)

5 (14.7)

10 (40.0)

4 (22.2)

< 0.001

Multiple intestinal lesions, %

22 (5.7)

7 (11.5)

6 (19.4)

11 (57.9)

0 (0.0)

9 (26.5)

3 (12.0)

5 (27.8)

< 0.001

  1. LDH: lactate dehydrogenase; IPI: International Prognostic Index; HI: high-intermediate; H: high; DLBCL: diffuse large B-cell lymphoma; MALT: extranodal marginal zone B-cell lymphoma; BL: Burkitt lymphoma; PTCL-U: peripheral T-cell lymphoma, unspecified; EATL: enteropathy-associated T-cell lymphoma; MCL: mantle cell lymphoma; ENKTL: extranodal natural killer/T-cell lymphoma; FL: follicular lymphoma